Ascendis Pharma A (ASND) Revenue (2014 - 2026)

Ascendis Pharma A (ASND) has 13 years of Revenue data on file, last reported at $288.7 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 171.87% year-over-year to $288.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 billion (up 122.73% YoY), and the FY2025 full-year result was $838.3 million, up 90.87% from the prior year.
• Revenue fell to $288.7 million in Q1 2026, from $484.8 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $484.8 million in Q4 2025 to a low of $6.6 million in Q2 2022.
• A 5-year average of $139.1 million and a median of $63.5 million in 2024 frame the typical range for Revenue.
• Across the five-year window, Revenue plunged 76.29% in 2022 and jumped 1294.35% in 2023, its largest moves.
• Tracing ASND's Revenue over 5 years: stood at $23.4 million in 2022, then soared by 1294.35% to $325.7 million in 2023, then gained by 1.7% to $331.2 million in 2024, then surged by 46.35% to $484.8 million in 2025, then slumped by 40.44% to $288.7 million in 2026.
• Business Quant data shows ASND's Revenue at $288.7 million in Q1 2026, $484.8 million in Q4 2025, and $249.7 million in Q3 2025.